



## PRECISION MEDICINE IN PROSTATE CANCER: Genomics, Technology and Evidence Based Practice

Friday 9 September 2022	
Session 1: Precision Medicine/Genomics	
0845 - 0850	<b>Welcome</b> <i>Meeting convenor – Sarat Chander</i>
0850 - 0920	<b>Plenary Session - Precision medicine and genomics in GU cancer</b>
0920 - 0940	<b>Plenary Session - Focal Lesional Boosting in Prostate Cancer</b>
0940 - 1000	<b>Challenges and limitations of the implementation of prostate biomarkers into clinical practice/trials</b>
1000 - 1015	<b>PSMA directed therapy - where are we now</b>
1015 - 1045	<i>Morning Refreshments</i>
Session 2: Prostate - Definitive XRT and Local Relapse	
1045 - 1115	<b>SBRT and adaptive RT in prostate cancer</b>
1115 - 1130	<b>Surgery and Post Radiation salvage</b>
1130 - 1150	<b>SBRT for post radiation salvage - WHO, WHEN and HOW</b>
1150 - 1245	<b>SBRT Prostate cancer challenging cases including a salvage case to compare and contrast salvage brachy vs SBRT vs surgery– Panel discussion</b>
1245 - 1345	<i>Lunch</i>
Session 3: Salvage Radiation Therapy	
1345 - 1415	<b>Lessons from the RADICALS, RAVES and GETUG</b>
1415 - 1435	<b>WHO and WHEN: A Surgeons Perspective</b> <b>Including role for adjuvant in setting of persistent PSA and pN+</b>
1435 - 1455	<b>Patterns of Local failure and impact on treatment volumes - Lessons from the PET department</b>

1455 - 1515	<b>Risk stratification in the salvage setting - Nodes and ADT</b>
1515 - 1530	<i>Afternoon Refreshments</i>
<b>Session 4 – Planning Workshop</b>	
1530 - 1700	<b>Radiation therapy planning workshop - post prostatectomy</b> <b>Discussion of anisotropic margins, nodal treatment volumes, dose and fractionation</b>
<b>Saturday 10 September 2022</b>	
<b>Session 5</b>	
0900 - 0930	<b>Lessons from STAMPEDE</b>
0930 - 1000	<b>To node or not to node - that is the question?</b>
1000 - 1025	<b>PCOR Australian radiation data results</b>
1025 - 1055	<i>Morning Refreshments</i>
<b>Session 6: FROGG Guidelines Session</b>	
1055 - 1110	<b>FROGG survey results</b>
1110 - 1225	<b>Revision of FROGG Post Prostatectomy Treatment Guidelines</b>
1225 - 1325	<i>Lunch</i>
<b>Session 7: Locally Advanced and Metastatic Prostate Cancer</b>	
1325 - 1355	<b>Metastasis directed therapy - oligometastatic disease and oligoprogression</b>
1355 - 1425	<b>Systemic therapy for metastatic disease - timing, sequencing and individualised care</b>
1425 - 1445	<b>Debate: USA vs ANZ</b> High risk prostate cancer - Cut it out / keep it in
1445 - 1510	<b>FROGG AGM</b> <i>FROGG Chairperson</i>
1510 - 1525	<i>Afternoon Refreshments</i>
1525 - 1625	<b>FROGG Executive Meeting</b>